DGAP-News: co.don AG

CO.DON AG - NICE publishes positive opinion on the use of Spherox

Berlin / Teltow, 15 January 2018 - The National Institute for Health and Care Excellence (NICE) in the UK has published a Final Appraisal Determination (FAD) for Spherox on 12 January 2018. NICE recommends use of autologous chondrocyte implantation (ACI) for adult patients with knee cartilage defects larger than 2 cm² who have not previously had surgery and does not have advanced stage arthritis.

NICE emphasise the innovative character of the ACI method and the unmet need for regenerative treatments. Furthermore, NICE determined that Spherox is a cost-effective therapy. The safety and efficacy of Spherox is proven in two clinical trials and recommended as a cost-effective use of NHS (National Health Service) resources. Spherox will therefore be available for a broad patient population.

Ralf Jakobs, CEO of CO.DON AG: "In July last year we received marketing authorisation from the European Medicines Agency (EMA). The positive opinion from NICE is another important milestone for CO.DON. It confirms the benefits of Spherox for patients and the healthcare society. The recommendation from NICE gives patients in England the opportunity to have knee cartilage defects treated autologously and sustainably and to return to everyday life activities again."

The FAD is available from the NICE website: www.nice.org.uk

CO.DON is science-driven biopharmaceutical company committed to research, development and commercialisation of autologous cell therapies for the repair of cartilage defects. Our products use only the patient's own cells and blood, is additive-free and the procedure is minimally invasive. Currently, over 11,000 patients have been treated in 200 clinics in Germany. In July 2017 we received marketing authorisation for the advanced therapy medicinal product, Spherox, from the European Medicine Agency.

The shares in CO.DON AG are listed on the Frankfurt Stock Exchange (ISIN: DE000A1K0227). Executive Board: Ralf M. Jakobs.

Further information is available from www.codon.eu

Investor Relations and Press Contact:
Matthias Meißner, M.A.
Corporate communications / IR / PR
Tel. +49 (0)30 240352330
Fax +49 (0)30 240352309
Email: ir@codon.de